Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.63 |
| ▸ | CTRC | Q99895 | 3/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745802 | 0.91 | F2 (0.65) | F2CTRCPRSS2F10 | |
| SCHEMBL6749637 | 0.90 | F2 (0.64) | F2CTRCPRSS2F10 | |
| SCHEMBL6924689 | 0.88 | F2 (0.66) | F2CTRCPRSS2F10 | |
| SCHEMBL6752156 | 0.86 | F2 (0.71) | F2CTRCPRSS2 | |
| SCHEMBL8476643 | 0.84 | F2 (0.73) | F2CTRCPRSS2F10 | |
| Acetic Acid SCHEMBL6745916 | 0.81 | F2 (0.59) | F2CTRCPRSS2F10 | |
| SCHEMBL6754691 | 0.80 | F2 (0.57) | F2CTRCPRSS2F10 | |
| SCHEMBL6745920 | 0.79 | F2 (0.62) | F2CTRCPRSS2F10 | |
| SCHEMBL5672793 | 0.78 | F2 (0.73) | F2CTRCPRSS2 | |
| SCHEMBL5672845 | 0.78 | F2 (0.71) | F2CTRCPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-01 | — | — | US | disclosed |
| US-6518310-B2 | Non-peptidic; inhibits trypsin-like protease, thrombin and embolus formation; anticoagulant | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-0944590-B1 | AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | F2 27/4885CTRC 69/4885PRSS2 65/4885 |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | F2 32/4885CTRC 91/4885PRSS2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.